单细胞转录组分析揭示免疫细胞对检查点抑制剂结肠炎上皮屏障功能障碍的不同贡献
该研究用单细胞多组学分析13例免疫检查点抑制剂结肠炎(irColitis)患者、8例ICI治疗对照和8例健康对照的结肠黏膜与血液约30万个细胞,发现irColitis患者黏膜调节性T细胞扩增、表达CXCL13和Th17基因程序的ITGAEHi CD8组织驻留记忆T细胞及再循环ITGB2Hi CD8 T细胞扩增,抗PD-1/CTLA-4联合治疗相关结肠炎中细胞毒性GNLYHi CD4 T细胞、再循环ITGB2Hi CD8 T细胞和表达缺氧基因程序的内皮细胞进一步扩增,管腔上皮细胞表达PCSK9、PD-L1和干扰素诱导特征并与凋亡、细胞更新增加和吸收不良相关。
要点
- irColitis患者结肠黏膜调节性T细胞扩增,ITGAEHi CD8组织驻留记忆T细胞表达CXCL13和Th17基因程序。
- 抗PD-1/CTLA-4联合治疗相关结肠炎中细胞毒性GNLYHi CD4 T细胞、再循环ITGB2Hi CD8 T细胞和缺氧基因程序内皮细胞进一步扩增。
- irColitis患者管腔上皮细胞表达PCSK9、PD-L1和干扰素诱导特征,与凋亡、细胞更新增加和吸收不良相关。
核心结论
- 这些数据提示循环T细胞和上皮-免疫细胞交互对PD-1/CTLA-4依赖性耐受和屏障功能具有关键作用,并识别出irColitis的潜在治疗靶点。
研究设计与样本
- 单细胞多组学分析约30万个细胞,来自13例发生irColitis的癌症患者(9例接受抗PD-1或抗CTLA-4单药治疗,4例接受双ICI联合治疗;多数患者为皮肤癌或肺癌)、8例接受ICI治疗的对照和8例健康对照的结肠黏膜与血液。
主要发现
- irColitis患者黏膜调节性T细胞扩增,表达CXCL13和Th17基因程序的ITGAEHi CD8组织驻留记忆T细胞及再循环ITGB2Hi CD8 T细胞扩增。
- 与抗PD-1治疗相比,抗PD-1/CTLA-4治疗相关结肠炎中细胞毒性GNLYHi CD4 T细胞、再循环ITGB2Hi CD8 T细胞和表达缺氧基因程序的内皮细胞进一步扩增。
- irColitis患者管腔上皮细胞表达PCSK9、PD-L1和干扰素诱导特征,与凋亡、细胞更新增加和吸收不良相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitor (ICI) therapy has revolutionized oncology, but treatments are limited by immune-related adverse events, including checkpoint inhibitor colitis (irColitis). Little is understood about the pathogenic mechanisms driving irColitis, which does not readily occur in model organisms, such as mice. To define molecular drivers of irColitis, we used single-cell multi-omics to profile approximately 300,000 cells from the colon mucosa and blood of 13 patients with cancer who developed irColitis (nine on anti-PD-1 or anti-CTLA-4 monotherapy and four on dual ICI therapy; most patients had skin or lung cancer), eight controls on ICI therapy and eight healthy controls. Patients with irColitis showed expanded mucosal Tregs, ITGAEHi CD8 tissue-resident memory T cells expressing CXCL13 and Th17 gene programs and recirculating ITGB2Hi CD8 T cells. Cytotoxic GNLYHi CD4 T cells, recirculating ITGB2Hi CD8 T cells and endothelial cells expressing hypoxia gene programs were further expanded in colitis associated with anti-PD-1/CTLA-4 therapy compared to anti-PD-1 therapy. Luminal epithelial cells in patients with irColitis expressed PCSK9, PD-L1 and interferon-induced signatures associated with apoptosis, increased cell turnover and malabsorption. Together, these data suggest roles for circulating T cells and epithelial-immune crosstalk critical to PD-1/CTLA-4-dependent tolerance and barrier function and identify potential therapeutic targets for irColitis.
引用
- Thomas MF, Slowikowski K, Manakongtreecheep K, et al. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis. Nat Med. 2024. PMID: 38724705. doi:10.1038/s41591-024-02895-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。